A glycan superbinder reveals polysialylated-CD56 as a precision biomarker for pancreatic cancer.

A polySia “superbinder” nanoMIP identifies polysialylated CD56 (polySia-CD56) as a specific, robust pancreatic cancer biomarker that outperforms CA19-9.

• Why it matters: Pancreatic cancer lacks reliable early-detection biomarkers, and polySia has been underexplored due to limited detection methods and recognition tools.
• What they did: The authors developed a nanoscale molecularly imprinted polymer (nanoMIP) with superior specificity and affinity for polySia versus monoclonal antibodies, then used it to quantify polySia-CD56 and compare it with multiple biomarkers including CA19-9.
• The result: polySia-CD56 shows an expression pattern complementary to CA19-9, and combining both biomarkers increases diagnostic accuracy to 94.1%, improving detection of CA19-9-negative patients.